1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies

Technology appraisal guidance [TA772] Published: 23 February 2022

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Tools and resources

Tools to help you put the guidance into practice.

Resource impact

  • Resource impact statement  

Guidance into practice

  • About the Into practice guide  
  • Practical steps to improving the quality of care and services using NICE guidance